Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016', provides in depth analysis on Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted pipeline therapeutics. The report provides comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects - The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Overview 8 Therapeutics Development 9 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Products under Development by Stage of Development 9 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Products under Development by Therapy Area 10 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Products under Development by Indication 11 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Products under Development by Companies 14 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Products under Development by Universities/Institutes 16 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 21 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development 23 Amgen Inc. 23 AstraZeneca Plc 24 Bristol-Myers Squibb Company 25 Eisai Co., Ltd. 26 Eli Lilly and Company 27 Genentech, Inc. 28 Johnson & Johnson 29 Merck & Co., Inc. 30 Novartis AG 31 Vitae Pharmaceuticals, Inc. 32 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles 33 AMG-8718 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 AVCRI-104P3 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 AVCRI-175P1 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 AZ-4217 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AZD-3293 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CNP-520 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 E-2609 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 ER-901356 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 GNE-892 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 JNJ-54861911 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 LY-2811376 + LY-3002813 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 LY-3202626 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecule to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecule to Inhibit BACE 1 for Alzheimer's Disease - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 TAK-070 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 verubecestat - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 VTP-36951 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Projects 59 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products 60 Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Featured News & Press Releases 61 Jun 14, 2016: New Alzheimer's Study Aimed at Preventing or Delaying Symptoms 61 Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer's disease 62 Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 "EPOCH" Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer's Disease 63 Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer's disease 63 May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug 64 Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer's Disease Therapy, MK-8931 64 Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer's Disease 65 Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research 66 Dec 03, 2012: Merck Initiates Phase II/III Study of Investigational BACE Inhibitor MK-8931 For Treatment Of Alzheimer's Disease 67 Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2012 67 Jul 13, 2012: Eisai To Present First Clinical Data For Bace Inhibitor E2609 At Alzheimer's Association International Conference 2012 68 Jun 08, 2012: Takeda Announces Transfer Of TAK-070 To National University Corporation 69 Apr 27, 2012: Merck Presents Results Of Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology 70 Feb 09, 2009: Ligand Earns $1 Million Milestone Payment On Progress Of Drug Candidate For Alzheimer's Disease 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Amgen Inc., H2 2016 23 Pipeline by AstraZeneca Plc, H2 2016 24 Pipeline by Bristol-Myers Squibb Company, H2 2016 25 Pipeline by Eisai Co., Ltd., H2 2016 26 Pipeline by Eli Lilly and Company, H2 2016 27 Pipeline by Genentech, Inc., H2 2016 28 Pipeline by Johnson & Johnson, H2 2016 29 Pipeline by Merck & Co., Inc., H2 2016 30 Pipeline by Novartis AG, H2 2016 31 Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 32 Dormant Projects, H2 2016 59 Discontinued Products, H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
